One of the first projects to be selected for funding under the European Innovative Medicines Initiative will address the challenges of developing drugs to treat schizophrenia and depression.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry
EPMA Journal Open Access 05 September 2017
-
Drug development in pediatric psychiatry: current status, future trends
Child and Adolescent Psychiatry and Mental Health Open Access 07 February 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat Rev Drug Discov 8, 523–524 (2009). https://doi.org/10.1038/nrd2939
Issue Date:
DOI: https://doi.org/10.1038/nrd2939
This article is cited by
-
New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation
The Pharmacogenomics Journal (2018)
-
Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry
EPMA Journal (2017)
-
Drug development in pediatric psychiatry: current status, future trends
Child and Adolescent Psychiatry and Mental Health (2012)
-
The Biomarkers Consortium: Practice and Pitfalls of Open-Source Precompetitive Collaboration
Clinical Pharmacology & Therapeutics (2010)
-
2009 in reflection
Nature Reviews Drug Discovery (2010)
